0 128

Cited 8 times in

A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group)

Authors
 Zhenjie Wu  ;  Qi Chen  ;  Hooman Djaladat  ;  Andrea Minervini  ;  Robert G. Uzzo  ;  Chandru P. Sundaram  ;  Koon H. Rha  ;  Mark L. Gonzalgo  ;  Reza Mehrazin  ;  Elio Mazzone  ;  Jamil Marcus  ;  Alyssa Danno  ;  James Porter  ;  Aeen Asghar  ;  Fady Ghali  ;  Georgi Guruli  ;  Antoin Douglawi  ;  Giovanni Cacciamani  ;  Alireza Ghoreifi  ;  Giuseppe Simone  ;  Vitaly Margulis  ;  Matteo Ferro  ;  Riccardo Tellini  ;  Andrea Mari  ;  Abhishek Srivastava  ;  James Steward  ;  Ali Al-Qathani  ;  Ahmad Al-Mujalhem  ;  Amit Satish Bhattu  ;  Alexander Mottrie  ;  Firas Abdollah  ;  Daniel D. Eun  ;  Ithaar Derweesh  ;  Alessandro Veccia  ;  Riccardo Autorino  ;  Linhui Wang 
Citation
 EUROPEAN UROLOGY FOCUS, Vol.8(1) : 173-181, 2022-01 
Journal Title
EUROPEAN UROLOGY FOCUS
Issue Date
2022-01
MeSH
Chemotherapy, Adjuvant ; Cisplatin* / therapeutic use ; Humans ; Kidney / physiology ; Kidney / surgery ; Nephrectomy / methods ; Nephroureterectomy* ; Nomograms ; Retrospective Studies
Keywords
Chemotherapy ; Functional outcome ; Radical nephroureterectomy ; Upper tract urinary carcinoma
Abstract
Background: Postoperative renal function impairment represents a main limitation for delivering adjuvant chemotherapy after radical nephroureterectomy (RNU).

Objective: To create a model predicting renal function decline after minimally invasive RNU.

Design, setting, and participants: A total of 490 patients with nonmetastatic UTUC who underwent minimally invasive RNU were identified from a collaborative database including 17 institutions worldwide (February 2006 to March 2020). Renal function insufficiency for cisplatin-based regimen was defined as estimated glomerular filtration rate (eGFR) <50 ml/min/1.73 m2 at 3 mo after RNU. Patients with baseline eGFR >50 ml/min/1.73 m2 (n = 361) were geographically divided into a training set (n = 226) and an independent external validation set (n = 135) for further analysis.

Outcome measurements and statistical analysis: Using transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines, a nomogram to predict postoperative eGFR <50 ml/min/1.73 m2 was built based on the coefficients of the least absolute shrinkage and selection operation (LASSO) logistic regression. The discrimination, calibration, and clinical use of the nomogram were investigated.

Results and limitations: The model that incorporated age, body mass index, preoperative eGFR, and hydroureteronephrosis was developed with an area under the curve of 0.771, which was confirmed to be 0.773 in the external validation set. The calibration curve demonstrated good agreement. Besides, the model was converted into a risk score with a cutoff value of 0.583, and the difference between the low- and high-risk groups both in overall death risk (hazard ratio [HR]: 4.59, p < 0.001) and cancer-specific death risk (HR: 5.19, p < 0.001) was statistically significant. The limitation mainly lies in its retrospective design.

Conclusions: A nomogram incorporating immediately available clinical variables can accurately predict renal insufficiency for cisplatin-based adjuvant chemotherapy after minimally invasive RNU and may serve as a tool facilitating patient selection.

Patient summary: We have developed a model for the prediction of renal function loss after radical nephroureterectomy to facilitate patient selection for perioperative chemotherapy.
Full Text
https://www.sciencedirect.com/science/article/pii/S2405456921000158
DOI
10.1016/j.euf.2021.01.014
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Rha, Koon Ho(나군호) ORCID logo https://orcid.org/0000-0001-8588-7584
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/194322
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links